Plasminogen Activator Inhibitor-2 Polymorphism Associates with Recurrent Coronary Event Risk in Patients with High HDL and C-Reactive Protein Levels

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Corsetti, James P ^a   Salzman, Peter ^a   Ryan, Dan ^a   Moss, Arthur J ^a   Zareba, Wojciech ^a   Sparks, Charles E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN P22; THROMBOSPONDIN; THROMBOSPONDIN 4; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; CYBA GENE; DISEASE MARKER; FEMALE; FIBRINOLYSIS; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LRP 1 GENE; MAJOR CLINICAL STUDY; MALE; PAI 2 GENE; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RECURRENT DISEASE; RISK ASSESSMENT; SERPINB GENE; THBS4 GENE;

AGED; ALLELES; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; FEMALE; GENOTYPE; HUMANS; INFLAMMATION; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 2; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84879950042     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068920     Document Type: Article

References (35)

1. Kontush A, Chapman MJ, (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58: 342-374. doi:10.1124/pr.58.3.1. PubMed: 16968945.
2. Rocha VZ, Libby P, (2009) Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 6: 399-409.
3. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM, (2011) HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8: 222-232.
4. Movva R, Rader DJ, (2008) Laboratory assessment of HDL heterogeneity and function. Clin Chem 54: 788-800. doi:10.1373/clinchem.2007.101923. PubMed: 18375481.
5. Smith JD, (2010) Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 30: 151-155. doi:10.1161/ATVBAHA.108.179226. PubMed: 19679832.
6. Ragbir S, Farmer JA, (2010) Dysfunctional high-density lipoprotein and atherosclerosis. Curr Atheroscler Rep 12: 343-348. doi:10.1007/s11883-010-0091-x. PubMed: 20506005.
7. Shao B, Oda MN, Oram JF, Heinecke JW, (2010) Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 23: 447-454. doi:10.1021/tx9003775. PubMed: 20043647.
8. Ansell BJ, Fonarow GC, Fogelman AM, (2007) The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 18: 427-434. doi:10.1097/MOL.0b013e3282364a17. PubMed: 17620860.
9. Corsetti JP, Gansevoort RT, Sparks CE, Dullaart RPF, (2010) Inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest 40: 483-489. doi:10.1111/j.1365-2362.2010.02287.x. PubMed: 20412290.
10. Corsetti JP, Gansevoort RT, Navis G, Sparks CE, Dullaart RPF, (2011) LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP. Atherosclerosis 214: 373-376. doi:10.1016/j.atherosclerosis.2010.11.029. PubMed: 21146168.
11. Corsetti JP, Ryan D, Rainwater DL, Moss AJ, Zareba W, et al. (2010) Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels. Arterioscler Thromb Vasc Biol 30: 1657-1664. doi:10.1161/ATVBAHA.110.207977. PubMed: 20489166.
12. Corsetti JP, Ryan D, Moss AJ, McCarthy J, Goldenberg I, et al. (2011) Thrombospondin-4 polymorphism (A387P) predicts cardiovascular risk in postinfarction patients with high HDL cholesterol and C-reactive protein levels. Thromb Haemost 106: 1170-1178. doi:10.1160/TH11-03-0206. PubMed: 22011848.
13. Nicholl SM, Roztocil E, Davies MG, (2006) Plasminogen activator system and vascular disease. Curr Vasc Pharmacol 4: 101-116. doi:10.2174/157016106776359880. PubMed: 16611153.
14. Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cosín R, et al. (2008) Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 15: 923-929. doi:10.2174/092986708783955455. PubMed: 18473800.
15. Vaughan DE, (2005) PAI-1 and atherothrombosis. J Thromb Haemost 3: 1879-1883. doi:10.1111/j.1538-7836.2005.01420.x. PubMed: 16102055.
16. Diebold I, Kraicun D, Bonello S, Görlach A, (2008) The 'PAI-1 paradox' in vascular remodeling. Thromb Haemost 100: 984-991. PubMed: 19132221.
17. Lee JA, Cochran BJ, Lobov S, Ranson M, (2011) Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma. Semin Thromb Hemost 37: 395-407. doi:10.1055/s-0031-1276589. PubMed: 21805446.
18. Boncela J, Przygodzka P, Papiewska-Pajak I, Wyroba E, Cierniewski CS, (2011) Association of plasminogen activator inhibitor type 2 (PAI-2) with proteasome within endothelial cells activated with inflammatory stimuli. J Biol Chem 286: 43164-43171. doi:10.1074/jbc.M111.245647. PubMed: 21976669.
19. Medcalf RL, Stasinopoulos SJ, (2005) The undecided serpin. Ins and Outs of Plasminogen Activator inhibitor Type 2. FEBS J 272: 4858-4867.
20. Medcalf RL, (2011) Plasminogen activator inhibitor type 2: still an enigmatic serpin but a model for gene regulation. Meths Enzymol 499: 105-134. doi:10.1016/B978-0-12-386471-0.00006-7. PubMed: 21683251.
21. Croucher DR, Saunders DN, Lobov S, Ranson M, (2008) Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer 8: 535-545. doi:10.1038/nrc2400. PubMed: 18548086.
22. Medcalf RL, Kruithof EK, Schleuning WD, (1988) Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes. J Exp Med 168: 751-759. doi:10.1084/jem.168.2.751. PubMed: 3137305.
23. Kruithof EK, Baker MS, Bunn CL, (1995) Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86: 4007-4024. PubMed: 7492756.
24. Lee JA, Croucher DR, Ranson M, (2010) Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes. Thromb Haemost 104: 1133-1142. doi:10.1160/TH10-02-0121. PubMed: 20838737.
25. Topol EJ, McCarthy J, Gabriel S, Moliterno DJ, Rogers WJ, et al. (2001) Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 104: 2641-2644. doi:10.1161/hc4701.100910. PubMed: 11723011.
26. McCarthy JJ, Parker A, Salem R, Moliterno DJ, Wang Q, et al. (2004) Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes. J Med Genet 41: 334-341. doi:10.1136/jmg.2003.016584. PubMed: 15121769.
27. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, et al. (1999) Thrombogenic factors and recurrent coronary events. Circulation 99: 2517-2522. doi:10.1161/01.CIR.99.19.2517. PubMed: 10330382.
28. Corsetti JP, Zareba W, Moss AJ, Sparks CE, (2005) Serum glucose and triglyceride determine high-risk subgroups in non-diabetic postinfarction patients. Atherosclerosis 183: 293-300. doi:10.1016/j.atherosclerosis.2005.03.046. PubMed: 15925371.
29. Corsetti JP, Ryan D, Moss AJ, Zareba W, Sparks CE, (2008) NAD(P)H oxidase polymorphism (C242T) and high HDL cholesterol associate with recurrent coronary events in postinfarction patients. Atherosclerosis 196: 461-468. doi:10.1016/j.atherosclerosis.2006.12.007. PubMed: 17214994.
30. Livak KJ, (1999) Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal Biomol Eng 14: 143-149. doi:10.1016/S1050-3862(98)00019-9. PubMed: 10084106.
31. Goldenberg I, Moss AJ, Block R, Ryan D, Corsetti JP, et al. (2007) Polymorphism in the cholesteryl ester transfer protein gene and the risk of early onset myocardial infarction among cigarette smokers. Ann Noninvas Electrocardiol 12: 364-374. doi:10.1111/j.1542-474X.2007.00186.x. PubMed: 17970962.
32. Harrell FE, Lee KL, Mark DB, (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med 15: 361-387. doi:10.1002/(SICI)1097-0258(19960229)15:4. PubMed: 8668867.
33. May M, Royston P, Egger M, Justice AC, Sterne J, (2004) Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Statist Med 23: 2375-2398. doi:10.1002/sim.1825.
34. Strickland DK, Kounnas MZ, Argraves WS, (1995) LDL receptor-related protein: a multiligand receptor for lipoprotein and proteinase catabolism. FASEB J 9: 890-898. PubMed: 7615159.
35. Llorente-Cortés V, Badimon L, (2005) LDL receptor-related protein and the vascular wall: implications for atherothrombosis. Arterioscler Thromb Vasc Biol 25: 497-504. doi:10.1161/01.ATV.0000154280.62072.fd. PubMed: 15705932.